Floatz logo

14 assets in Severe Combined Immunodeficiency

Therapeutic assets addressing Severe Combined Immunodeficiency, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fludarabine
Severe Combined Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)P2/3BB (69)
Alemtuzumab
Severe Combined Immunodeficiency
Washington University School of MedicineP2/3BB (67)
Nivestim
Severe Combined Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)P2BB (67)
Busulfanum
Severe Combined Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)P2/3BB (65)
Cyclophosphamide
Severe Combined Immunodeficiency
St. Jude Children's Research HospitalP2/3BB (65)
Thiotepa
Severe Combined Immunodeficiency
St. Jude Children's Research HospitalP2BB (64)
Sirolimus
Severe Combined Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)P2B (60)
Melphalan
Severe Combined Immunodeficiency
Washington University School of MedicineP2B (57)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Severe Combined Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)P1/2CCC (48)
Aproart-Cd34
Severe Combined Immunodeficiency
University of California, San FranciscoP1/2CCC (48)
cd3/cd19 negative allogeneic hematopoietic stem cells
Severe Combined Immunodeficiency
Paul SzabolcsP1/2CCC (48)
Mesna
Severe Combined Immunodeficiency
Masonic Cancer Center, University of MinnesotaN/AD (30)